Dyne Therapeutics, Inc. cash flow to debt ratio of -1.99K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Dyne Therapeutics, Inc.'s free cash flow has decreased 37.45% from $-294.75M last year to $-405.13M, signaling decreasing performance

Dyne Therapeutics, Inc.'s debt to equity ratio is 0.03, which means that the company's assets are healthy financed, signaling financial stability.

Dyne Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.04 last year to 0.03 today, signaling strengthened financials

Dyne Therapeutics, Inc. has a net cash position, so leverage is healthy.

Dyne Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Dyne Therapeutics, Inc. has insufficient data to evaluate this check.

Dyne Therapeutics, Inc.'s short-term assets of $1.13B exceed its short-term liabilities of $50.62M

Dyne Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Dyne Therapeutics, Inc.'s return on equity of -64.30%, is lower than 15.00%, indicating bad performance

Dyne Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Dyne Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Dyne Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Dyne Therapeutics, Inc. has negative free cash flow, indicating cash burn

Dyne Therapeutics, Inc.'s yearly earnings has decreased 40.58% since last year from $-317.42M to $-446.21M, signaling decreasing performance

Dyne Therapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -58.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Dyne Therapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Dyne Therapeutics, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Dyne Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Dyne Therapeutics, Inc. has insufficient data to evaluate this check.

Dyne Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dyne Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Dyne Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Dyne Therapeutics, Inc. has insufficient data to evaluate this check.

Dyne Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Dyne Therapeutics, Inc. has a price-to-book ratio of 6.24x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Dyne Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue